dm+d

Unassigned

New Medicines

EstybonRefractory myelodysplastic syndromes (MDS), high-risk

Information

Estybon
New molecular entity
Baxalta
Onconova

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Yes
Jan 21No longer listed in company pipeline for MDS; assume all development discontinued in this indication [22].

Category

Phosphatidylinositol 3 kinase inhibitor
Approximately 60-70% of patients are classified as primary myelodysplastic syndrome (MDS). The estimated incidence of MDS increases significantly with age, ranging from 0.7/100,000 during the fourth decade to 20.8-36.3/100,000 in those aged over 70 years. [3]
Refractory myelodysplastic syndromes (MDS), high-risk
Intravenous infusion

Further information

Yes

Trial or other data

Aug 20PIII INSPIRE study fails to to meet primary endpoint of significantly improved survival vs best supportive care in higher-risk MDS. In the intent-to-treat analysis, patients randomised to IV rigosertib achieved OS of 6.4 months vs. 6.3 months for physician´s choice (p=0.33) in overall population [20].

Evidence based evaluations